Experts in acute lymphoblastic leukemia examine the logistical challenges associated with CAR T-cell therapy delivery and assess the frequency of patient attrition due to manufacturing delays.
What are some logistical barriers with delivery of CAR T-cell Therapy?
How frequently do your patients have to drop out from CAR T-cell therapy due to manufacturing time? How does it compare to the rates in the ZUMA-3 and FELIX Study?
How feasible is it for your patients to remain in close proximity to the hospital per the REMS requirements?
Have you observed any additional or unique access challenges in minority populations?